China’s standard of living is continuing to rise. Along with this rise, the country’s citizens are demanding higher standards of medical and healthcare services. The government has taken note and related policy reform and policy implementation has taken centre stage.
China has a huge population, which does present challenges for the improvement of the healthcare system in the country. However, given the economic, demographic and policy fundamentals, we believe China will continue to provide favourable opportunities for multinational healthcare companies to realise sustained growth.
We have already witnessed several multinational healthcare companies, such as Johnson & Johnson, GE Healthcare, GlaxoSmithKline, Merck, Eli Lilly, Medtronic and AstraZeneca, invest heavily in the China marketplace in recent years, with several citing China as one of their top three markets globally in terms of total revenue contribution.
During the first quarter of this year, we conducted a comprehensive and forward-looking eight-question business survey of multinational healthcare companies with operations in China. The survey was all-encompassing in terms of business sub-sector and company size.
Source : DTZ (Groupe UGL)